Celgene's Pomalyst (pomalidomide)-Based Triple Regimen Receive Health Canada's Approval for Multiple Myeloma
Shots:
- The approval is based on P-III OPTIMISMM study results assessing Pomalyst + bortezomib and dexamethasone vs bortezomib + dexamethasone in 559 patients in a ratio (1:1) with 2L+ MM and prior treated with/or refractory to Revlimid (lenalidomide)
- The P-III OPTIMISMM study results: mPFS (11.2 mos. vs 7.1 mos.)- reduction in diseases progression by 39%- patients with 1L therapy- mPFS (20.73 mos. vs 11.63mos.)
- Pomalyst is an immunomodulatory therapy act by enhancing T-cell & NK-cell mediated immunity- indicated to treat MM as triple regimen therapy with Takeda's Velcade (bortezomib) and dexamethasone
Click here to read full press release/ article | Ref: Canada Newswire | Image: QUAPE
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com